Recurrent Non-small Cell Lung Cancer Terminated Phase 1 / 2 Trials for Erlotinib (DB00530)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01471964Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerTreatment